Double if not triple. Volume will shoot up as will stock price when the average investor hears BTX next-gen cancer diagnostic products hit the market in late 2015.
And when this happens BTX will then have the $ to push heart, cartilage and other regen therapies forward. Once in a life time here.
PanC-DX has a home in top hospitals such as Weil Cornell and Cancer Institute in Spain
Jepro, pumper?..no just a simple fact, BTX releases to market next-gen cancer diagnostic products by end of 2015 and stock triples from current price. And again PanC-DX is low hanging fruit that will before long pull in billions paving the way for Biotimes stem cell regen products that will revolutionize medicine. Within 5 years BTX's off the shelf cartilage/tendon regen products will begin supplying the NFL, NBA and other sports leagues around the world.
Pumper, no just a very informed investor
Will be one of the most extensive/cutting edge genetic medical apps to hit the market. Very cool!
Both LifeMap and PanC-DX marketing plans to be unveiled soon, IMO, this will take us to the next level of $6-8, and that might be low balling it.
To bb and his other alias shorters: NOT getting my shares!
After 7 years of R&D we acquired the worlds best IP......liftoff commencing!
CUR, STEM, GERN, KOOL, CYTX, ASTM, ACTC, TNGN, BCLI..
All stem cell companies I know pale in comparison.
BTX owns AST, seems lopsided now but will even out in one months time, hang in there!
OncoCyte PanC patents to be confirmed, that will be huge factor. Technically genes can't be pAtented, but the proprietary gene marker method for testing can be. Once these patents come through all out buying blitz.
Those bash and buyers clowns have been using BTX as a chew toy for too long, later this year as we move above $10 and become more stable you will be seeing less of them guarenteed.
BB, being that you have played BTX for close to a decade, I trust you keep on coming back as you have trust in Dr. west and the empire he has built. What do you think of Cancer diagnostics PanC-DX and do you think OncoCyte will make as successful IPO as AST has been?
This kind of next gen regen therapy will be on BTX front burner in 6 mo after cancer diagnostic products and genetic medical app start their marketing phase.